HTR1A Gene
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HTR1A — Serotonin Receptor 1A</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HTR1A</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>5-Hydroxytryptamine Receptor 1A</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>5q12.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/3350" target="_blank">3350</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178394" target="_blank">ENSG00000178394</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08908" target="_blank">P08908</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Depression](/diseases/depression), [Anxiety](/diseases/anxiety), [Parkinson's Disease](/diseases/parkinsons-disease), [Alzheimer's Disease](/diseases/alzheimers)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Raphe nuclei, Hippocampus, Cortex, Amygdala</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
HTR1A — Serotonin Receptor 1A
Introduction
Htr1A Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
HTR1A (5-Hydroxytryptamine Receptor 1A) encodes the 5-HT1A serotonin receptor, a G protein-coupled receptor (GPCR) that inhibits adenylyl cyclase through Gi/Go protein signaling. It is the most abundant serotonin receptor in the brain and critical for mood, anxiety, and cognitive function["@barnes1999"]. The 5-HT1A receptor is expressed both as a presynaptic autoreceptor on serotoninergic [neurons](/entities/neurons) in the raphe nuclei and as a postsynaptic receptor in various target regions["@albert2021"].
Gene Structure
The HTR1A gene is located on chromosome 5q12.3 and consists of:
- Exons: 1 (single-exon gene)
- Promoter region: Contains regulatory elements for neuron-specific expression
- Transcript length: ~2.8 kb
- Protein product: 421 amino acids
The gene promoter contains binding sites for transcription factors including CREB, [NF-κB](/entities/nf-kb), and GATA, allowing dynamic regulation in response to stress and pharmacological treatments[@lemonde2003].
Protein Structure
The 5-HT1A receptor contains the classic seven-transmembrane domain structure of GPCRs:
| Domain | Function |
|--------|----------|
| N-terminus | Extracellular, glycosylation sites |
| TM1-TM7 | Seven transmembrane helices |
| Extracellular loops | Ligand binding pocket formation |
| Intracellular loops | G protein coupling (Gi/Go) |
| C-terminus | Phosphorylation sites, protein interactions |
The ligand binding pocket is formed within the transmembrane domains, with key residues in TM3, TM5, TM6, and TM7 mediating agonist and antagonist binding[@shapiro2002].
Normal Function
Signaling Pathways
The 5-HT1A receptor couples to Gi/Go proteins, leading to:
Adenylyl cyclase inhibition: Decreased cAMP production
MAPK/ERK activation: Through βγ subunits
Ion channel modulation: Activation of GIRK channels causing hyperpolarization
PI3K/Akt pathway: Mediating neuroprotective effectsPresynaptic Autoreceptor Function
In the dorsal and median raphe nuclei, 5-HT1A autoreceptors:
- Sense extracellular serotonin levels
- Inhibit serotonin release through negative feedback
- Modulate firing rate of serotoninergic neurons
- Mediate anxiolytic effects of certain compounds
Postsynaptic Receptor Function
In target regions, postsynaptic 5-HT1A receptors mediate:
| Brain Region | Function |
|--------------|----------|
| [Hippocampus](/brain-regions/hippocampus) | Learning, memory, neurogenesis |
| Amygdala | Emotional processing, fear extinction |
| Prefrontal [cortex](/brain-regions/cortex) | Cognitive flexibility, decision-making |
| Hypothalamus | Stress response, neuroendocrine regulation |
Brain Distribution
The 5-HT1A receptor shows region-specific expression:
- Raphe nuclei: Highest density (presynaptic autoreceptor)
- Hippocampus: CA1, CA3, dentate gyrus (postsynaptic)
- Amygdala: Basolateral complex
- Prefrontal cortex: Layer-specific expression
- Septal nuclei: Moderate density
Disease Associations
Depression and Anxiety
- 5-HT1A autoreceptor dysfunction: Implicated in treatment-resistant depression
- Polymorphisms: A-1018G promoter variant associated with depression susceptibility
- SSRIs effect: Chronic SSRI treatment desensitizes autoreceptors
- Partial agonists: Buspirone, vilazodone used therapeutically[@blier2003]
Parkinson's Disease
- Levodopa-induced dyskinesias: 5-HT1A agonists reduce dyskinesias
- Neuroprotection: Activation provides neuroprotective effects in models
- Non-motor symptoms: Potential for treating depression in PD patients
- Clinical trials: Tandospirone showing promise[@santini2012]
Alzheimer's Disease
- Cognitive enhancement: 5-HT1A activation improves memory
- Cholinergic interaction: Synergistic effects with cholinergic drugs
- Amyloid effects: [Aβ](/proteins/amyloid-beta) may alter 5-HT1A signaling
- Neurogenesis: Promotes hippocampal neurogenesis[@oleary2020]
Other Neurological Disorders
- Schizophrenia: Altered receptor density in prefrontal cortex
- Bipolar disorder: Mood stabilizer effects involve 5-HT1A
- Migraine: 5-HT1A agonists used in acute treatment
- Insomnia: Role in sleep-wake cycle regulation
Therapeutic Targeting
Approved Drugs
| Drug | Mechanism | Indication |
|------|-----------|------------|
| Buspirone | 5-HT1A partial agonist | Anxiety disorders |
| Vilazodone | SSRI + 5-HT1A partial agonist | Major depressive disorder |
| Vortioxetine | SSRI + 5-HT1A agonist | Depression |
| Tandospirone | 5-HT1A agonist | Anxiety, potential for PD |
Novel Therapeutics
- F-15599: Highly selective 5-HT1A agonist for cognitive enhancement
- NLX-101: PET ligand for imaging 5-HT1A density
- Gene therapy: Viral vector delivery for sustained receptor activation
Drug Development Challenges
- Balancing autoreceptor vs postsynaptic effects
- Achieving adequate brain penetration
- Avoiding desensitization with chronic treatment
Research Directions
Current Questions
How do 5-HT1A receptor polymorphisms influence treatment response?
Can selective postsynaptic agonists provide cognitive benefits without autoreceptor side effects?
What is the precise role of 5-HT1A in neurodegeneration?Experimental Approaches
- Knockout mice: Understanding receptor function
- PET imaging: In vivo receptor density mapping
- iPSC models: Patient-derived neurons for disease modeling
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Depression](/diseases/depression)
- [Anxiety](/cell-types/bnst-anxiety)
- [Serotonin Signaling](/mechanisms/serotonin-signaling)
- [Raphe Nuclei](/cell-types/raphe-nuclei)
- [5-HT2A Receptor](/proteins/5-ht2a-receptor)
- [Monoamine Oxidase Inhibitors](/therapeutics/maoi)
External Links
- [NCBI Gene: HTR1A](https://www.ncbi.nlm.nih.gov/gene/3350)
- [UniProt: HTR1A](https://www.uniprot.org/uniprot/P08908)
- [IUPHAR: HTR1A](https://www.guidetopharmacology.org/GTOF/8)
- [GeneCards: HTR1A](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HTR1A)
Background
The study of Htr1A Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Barnes NM, Sharp T, A review of central 5-HT receptors and their function (1999)](https://pubmed.ncbi.nlm.nih.gov/10462127/)
[Albert PR, Le Francois B, Millar AM, Transcriptional dysregulation of 5-HT1A autoreceptor in depression (2021)](https://pubmed.ncbi.nlm.nih.gov/33202215/)
[Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR, Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide (2003)](https://pubmed.ncbi.nlm.nih.gov/14507979/)
[Shapiro DA, Kristiansen K, Krobert KA, Roth BL, The 5-HT1A receptor signaling complex: a modular approach (2002)](https://pubmed.ncbi.nlm.nih.gov/12070526/)
[Blier P, Ward NM, Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry (2003)](https://pubmed.ncbi.nlm.nih.gov/12559647/)
[Santini E, Rylander D, Alvaro G, Cenci MA, The 5-HT1A receptor agonist, NLX-101, reduces L-DOPA-induced dyskinesia in the 6-OHDA rat model (2012)](https://pubmed.ncbi.nlm.nih.gov/22531258/)
[O'Leary OF, Zano S, Pothuizen AGM, Naffah-Manzacchi T, Felice D, 5-HT1A receptors in the dorsal raphe nucleus and mood in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32039829/)Pathway Diagram
The following diagram shows the key molecular relationships involving HTR1A Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)